Valuation : Celgene

Market Cap 7.7TCr 6.63TCr 6.23TCr 5.69TCr 11TCr 7,28600Cr 11TCr 74TCr 29TCr 3,73100Cr 29TCr 28TCr 11,88400Cr P/E 2017
28.7x
P/E 2018 11.6x
Enterprise Value 9.13TCr 7.85TCr 7.38TCr 6.74TCr 13TCr 8,63100Cr 13TCr 88TCr 34TCr 4,42000Cr 34TCr 34TCr 14,07800Cr EV / Sales 2017
6.61x
EV / Sales 2018 3.86x
Free-Float
-
Yield 2017 *
-
Yield 2018 -
15/23/15 Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation CI
08/21/08 Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation CI
22/21/22 Celgene Corporation Will Grant Sun Pharmaceutical Industries Limited A License to Celgene's Patents Required to Manufacture and Sell Certain Limited Quantity CI
23/21/23 Celgene Corporation Issues Notice of Redemption of Notes CI
04/21/04 Bristol-Myers Squibb Company and Celgene Corporation Announce Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion CI
05/21/05 Ikena Oncology, Inc. announced that it has received $120 million in funding from a group of investors CI
23/20/23 Amgen : Signs Licensing Agreement With Medicines Development for Global Health MT
05/20/05 Bristol Myers Squibb : Q3 Results Beat Estimates; Raises 2020 EPS Outlook MT
23/20/23 Silverback Therapeutics, Inc. announced that it has received $84.999996 million in funding from a group of investors CI
22/20/22 Silverback Therapeutics, Inc. announced that it expects to receive $84.999996 million in funding from a group of investors CI
26/20/26 Agios Pharmaceuticals, Inc. Provides Update on 2016 Collaboration Agreement with Celgene CI
11/20/11 Silverback Therapeutics, Inc. announced that it has received $68.400013 million in funding from a group of investors CI
04/20/04 Pulmonary Fibrosis Foundation Launches Industry Consortium to Identify Biomarkers in Pulmonary Fibrosis CI

Financials

2017 2018
Net sales 1.3TCr 1.12TCr 1.05TCr 960.1Cr 1.8TCr 1,23000Cr 1.8TCr 12TCr 4.82TCr 63TCr 4.88TCr 4.78TCr 2,00600Cr 1.53TCr 1.31TCr 1.24TCr 1.13TCr 2.11TCr 1,44500Cr 2.12TCr 15TCr 5.66TCr 74TCr 5.74TCr 5.61TCr 2,35700Cr
Net income 294Cr 252.84Cr 237.8Cr 217.08Cr 405.99Cr 28TCr 407.31Cr 2.82TCr 1.09TCr 14TCr 1.1TCr 1.08TCr 45TCr 404.6Cr 347.96Cr 327.26Cr 298.74Cr 558.72Cr 38TCr 560.53Cr 3.88TCr 1.5TCr 20TCr 1.52TCr 1.49TCr 62TCr
Net Debt 379.3Cr 326.2Cr 306.8Cr 280.06Cr 523.79Cr 36TCr 525.48Cr 3.64TCr 1.41TCr 18TCr 1.42TCr 1.39TCr 59TCr 1.42TCr 1.22TCr 1.15TCr 1.05TCr 1.96TCr 1,34500Cr 1.97TCr 14TCr 5.27TCr 69TCr 5.34TCr 5.22TCr 2,19400Cr
Logo Celgene
Celgene Corporation specializes in the design, development, and sale of products for treating cancer and immune system disorders. Net sales break down by product family as follows: - therapeutic products (99.9%); - other (0.1%): cellular therapy products and biological materials for implants, for tissue and organ treatments, and for therapeutic product development. Net sales are distributed geographically as follows: the United States (65.6%), Europe (24.7%) and other (9.7%).
Employees
-
Sector
-
  1. Stock Market
  2. Stocks
  3. CELG Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!